NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
6.50
Dollar change
+0.03
Percentage change
0.46
%
IndexRUT P/E- EPS (ttm)-0.67 Insider Own26.34% Shs Outstand101.35M Perf Week0.31%
Market Cap658.86M Forward P/E- EPS next Y-0.84 Insider Trans-0.18% Shs Float74.66M Perf Month0.31%
Enterprise Value188.76M PEG- EPS next Q-0.35 Inst Own84.00% Short Float16.89% Perf Quarter-19.45%
Income-69.08M P/S4.07 EPS this Y-35.23% Inst Trans0.35% Short Ratio9.36 Perf Half Y-48.70%
Sales161.92M P/B1.37 EPS next Y39.36% ROA-16.05% Short Interest12.61M Perf YTD-48.70%
Book/sh4.73 P/C1.39 EPS next 5Y- ROE-17.80% 52W High16.76 -61.22% Perf Year-51.64%
Cash/sh4.67 P/FCF- EPS past 3/5Y28.09% -38.09% ROIC-14.32% 52W Low6.08 6.91% Perf 3Y-62.75%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin94.96% Volatility3.12% 4.54% Perf 5Y-
Dividend TTM- EV/Sales1.17 EPS Y/Y TTM73.23% Oper. Margin-118.31% ATR (14)0.30 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.55 Sales Y/Y TTM- Profit Margin-42.66% RSI (14)44.87 Recom1.22
Dividend Gr. 3/5Y- - Current Ratio10.62 EPS Q/Q51.32% SMA20-2.95% Beta-1.27 Target Price28.00
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-4.39% Rel Volume1.00 Prev Close6.47
Employees181 LT Debt/Eq0.01 EarningsMay 06 AMC SMA200-39.83% Avg Volume1.35M Price6.50
IPOMay 27, 2021 Option/ShortYes / Yes EPS/Sales Surpr.20.07% 1.63% Trades Volume1,399,658 Change0.46%
Date Action Analyst Rating Change Price Target Change
Oct-09-24Reiterated Needham Buy $32 → $33
Aug-01-24Upgrade BofA Securities Underperform → Buy $11 → $24
Apr-24-24Reiterated Needham Buy $30 → $33
Apr-25-23Downgrade BofA Securities Buy → Underperform $34 → $9
Feb-08-23Initiated CapitalOne Overweight $40
Feb-03-23Initiated Oppenheimer Perform
Dec-15-22Initiated H.C. Wainwright Buy $35
Dec-14-22Initiated Needham Buy $40
Dec-05-22Initiated Goldman Buy $45
Dec-01-22Initiated BofA Securities Buy $34
Jun-10-25 08:30AM
May-13-25 10:47AM
May-09-25 07:54AM
May-07-25 11:09AM
03:21AM
05:25PM Loading…
May-06-25 05:25PM
04:01PM
May-05-25 10:00AM
May-03-25 02:13AM
Apr-23-25 02:58PM
Apr-22-25 08:30AM
Apr-10-25 11:51PM
Apr-09-25 09:44AM
Apr-08-25 12:24AM
Mar-20-25 01:00AM
09:00AM Loading…
Mar-05-25 09:00AM
Feb-25-25 05:55PM
04:05PM
01:36AM
Feb-13-25 09:55AM
Feb-11-25 08:30AM
Jan-28-25 08:56AM
05:30AM
Jan-23-25 01:02AM
Jan-22-25 08:44AM
Jan-20-25 03:31PM
Jan-13-25 08:00AM
Dec-24-24 04:30PM
Dec-22-24 03:30PM
Dec-19-24 03:19PM
08:30AM Loading…
Dec-17-24 08:30AM
Dec-16-24 09:49AM
Dec-06-24 08:53PM
Nov-27-24 10:18AM
Nov-20-24 04:30PM
Nov-18-24 08:30AM
Nov-06-24 09:55AM
Oct-30-24 05:20PM
04:01PM
Oct-21-24 09:55AM
Oct-16-24 08:44AM
08:30AM
Oct-01-24 08:00PM
Aug-27-24 12:49PM
Aug-19-24 11:15AM
Aug-14-24 11:46AM
Jul-30-24 01:52PM
08:40AM
07:30AM
07:00AM
Jul-25-24 11:53AM
12:58AM
Jun-27-24 09:51AM
Jun-24-24 04:50PM
Jun-22-24 04:11AM
Jun-19-24 12:14PM
10:29AM
Jun-18-24 08:30AM
Jun-11-24 07:46AM
May-30-24 08:30AM
May-07-24 09:25AM
May-06-24 10:53PM
04:30PM
03:22AM
May-04-24 02:31AM
Apr-23-24 03:56PM
03:54PM
Mar-13-24 07:07AM
Feb-28-24 04:32AM
Feb-26-24 04:30PM
Jan-31-24 05:12PM
Jan-17-24 08:00AM
Dec-19-23 08:00AM
Nov-27-23 10:00AM
Nov-17-23 07:00AM
Nov-14-23 08:00AM
Nov-06-23 05:16PM
04:30PM
Nov-04-23 12:16PM
Oct-30-23 07:27PM
08:00AM
Oct-23-23 01:20PM
Oct-20-23 10:20AM
Sep-29-23 12:43PM
Sep-11-23 09:02PM
Aug-16-23 08:00AM
Aug-10-23 02:28PM
Aug-07-23 04:30PM
Jun-17-23 08:29AM
Jun-12-23 08:00AM
Jun-08-23 12:38PM
07:00AM
Jun-06-23 10:31PM
04:01PM
Jun-05-23 04:06PM
12:30PM
Jun-04-23 12:45PM
May-30-23 08:00AM
May-25-23 08:30PM
05:00PM
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Merendino LaurenChief Commercial OfficerMay 16 '25Sale6.263,92724,57535,161May 19 05:54 PM
Dubow AdamGENERAL COUNSELMay 16 '25Sale6.264,55228,48647,136May 19 05:48 PM
York Charles N IICOO, CFO AND SECRETARYMay 16 '25Sale6.264,28226,796265,231May 19 05:45 PM
Bender JeremyCHIEF EXECUTIVE OFFICERMay 16 '25Sale6.2613,96487,385145,737May 19 05:44 PM
CHARLES YORKOfficerMay 16 '25Proposed Sale6.264,28226,796May 16 04:09 PM
LAUREN MERENDINOOfficerMay 16 '25Proposed Sale6.263,92724,575May 16 04:09 PM
ADAM DUBOWOfficerMay 16 '25Proposed Sale6.264,55228,486May 16 04:08 PM
JEREMY BENDEROfficerMay 16 '25Proposed Sale6.2613,96487,385May 16 04:08 PM
York Charles N IICOO, CFO AND SECRETARYFeb 18 '25Sale11.964,37052,278252,638Feb 21 06:10 PM
Dubow AdamGENERAL COUNSELFeb 18 '25Sale11.964,64655,58039,602Feb 21 06:08 PM
Bender JeremyCHIEF EXECUTIVE OFFICERFeb 18 '25Sale11.9612,048144,130128,015Feb 21 06:05 PM
ADAM DUBOWOfficerFeb 18 '25Proposed Sale11.964,64655,580Feb 18 06:07 PM
CHARLES YORKOfficerFeb 18 '25Proposed Sale11.964,37052,278Feb 18 06:04 PM
JEREMY BENDEROfficerFeb 18 '25Proposed Sale11.9612,048144,129Feb 18 06:02 PM
Blackman Samuel C.HEAD OF R&DDec 10 '24Sale13.3130,000399,3391,034,015Dec 12 04:06 PM
Bender JeremyCHIEF EXECUTIVE OFFICERNov 18 '24Sale13.2110,554139,420108,377Nov 19 04:36 PM
Blackman Samuel C.HEAD OF R&DNov 18 '24Sale13.212,20629,1421,064,015Nov 19 04:34 PM
Dubow AdamGENERAL COUNSELNov 18 '24Sale13.213,16541,81032,162Nov 19 04:32 PM
York Charles N IICOO, CFO AND SECRETARYNov 18 '24Sale13.212,60234,373240,133Nov 19 04:30 PM
SAMUEL BLACKMANOfficerNov 18 '24Proposed Sale13.212,20629,142Nov 18 04:22 PM
JEREMY BENDEROfficerNov 18 '24Proposed Sale13.2110,554139,420Nov 18 04:21 PM
Blackman Samuel C.HEAD OF R&DNov 08 '24Sale16.1718,255295,2291,067,535Nov 12 04:57 PM
Blackman Samuel C.HEAD OF R&DNov 11 '24Sale16.1010,000160,9941,057,535Nov 12 04:57 PM
SAMUEL BLACKMANOfficerNov 11 '24Proposed Sale16.3950,000819,500Nov 12 07:49 AM
Blackman Samuel C.HEAD OF R&DNov 07 '24Sale16.0311,245180,2871,085,790Nov 08 04:15 PM
Blackman Samuel C.HEAD OF R&DOct 31 '24Sale16.025008,0101,097,035Nov 04 05:24 PM
SAMUEL BLACKMANOfficerOct 31 '24Proposed Sale14.4730,000434,100Oct 31 04:27 PM
Blackman Samuel C.HEAD OF R&DSep 10 '24Sale14.2230,000426,6751,097,535Sep 12 04:48 PM
Dubow AdamGENERAL COUNSELAug 16 '24Sale14.003,20244,82526,928Aug 19 06:12 PM
York Charles N IICOO, CFO AND SECRETARYAug 16 '24Sale14.002,63336,860232,485Aug 19 06:07 PM
Blackman Samuel C.HEAD OF R&DAug 16 '24Sale14.002,23231,2461,127,535Aug 19 05:59 PM
Bender JeremyCHIEF EXECUTIVE OFFICERAug 16 '24Sale14.0010,681149,52498,932Aug 19 05:53 PM
JEREMY BENDEROfficerAug 16 '24Proposed Sale14.0010,681149,524Aug 16 05:23 PM
SAMUEL BLACKMANOfficerAug 16 '24Proposed Sale14.002,23231,246Aug 16 05:17 PM
Blackman Samuel C.HEAD OF R&DJul 16 '24Sale16.0120,000320,2261,121,081Jul 17 04:53 PM